glp-1 forms PDB-101: Molecule of the Month: Receptor Agonists GLP-1 Agonists Explained: Definition, How
Description
Current and future pharmacological therapies for NAFLD/NASH
Matzinger D, Degen L, Drewe J, Meuli J, Duebendorfer R, Ruckstuhl N, et al
Hypothalamic Y2 receptors regulate bone formation
Researchers also found the proportion of users of GLP-1 medications without FDA-approved indications rose from 0.21% in 2019 to 0.37% in 2023
